ArticleThe Journal of clinical investigation2026
Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.
Styliani Karanika et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.